2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5661 An easy multiparametric score to distinguish accelerated-CLL from Richter transformation: An Italian multicenter study.

Idanna Innocenti, MD, PhD, Annamaria Tomasso2, Tommaso Quaranta3, Pierluigi Abbate4, Francesco Angotzi5, Andrea Serafin6, Raffaella Pasquale7, Massimo Moratti8, Luca Stirparo9, Massimo Gentile10, Florenzia Vuono11, Arianna Di Napoli, MD12, Arianna Bakacs13, Diana Giannarelli14, Alberto Fresa, MD15, Antonio Pinto, MD16, Gioacchino Catania17, Jacopo Olivieri, MD18, Marta Coscia, MD19, Arianna Bevilacqua20, Francesco Autore, MD21, Alessandro Cellini, MD22, Giulia Zamprogna23, Dimitar Efremov, MD,PhD24, Enrico Lista25, Valter Gattei, MD26, Livio Trentin, MD27, Andrea Visentin, MD,PhD28, Luca Laurenti Sr, MD29
1 Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy
2 Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy, Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy
3 Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy
4 Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy
5 Hematology Unit, Department of Medicine University of Padova, Padova, Italy
6 Hematology Unit, Department of Medicine University of Padova, Padova, Italy
7 SOC Clinica Ematologica – Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
8 Dipartimento di Medicina, DMED, Università degli Studi di Udine, Udine, Italy
9 Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy
10 Azienda Ospedaliera di Cosenza, Cosenza, Italy, Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy
11 Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy
12 Department of Clinical and Molecular Medicine, Sapienza University, School of Medicine and Psychology, Sant' Andrea University Hospital, Roma, Italy
13 Fondazione Policlinico Universitario 'Agostino Gemelli'- IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
14 Design and Analysis of Clinical Trials Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy
15 Hematology-Oncology and Stem Cell Transplantation Unit, Department of Onco-Hemotology and Innovative Diagnostics, Istituto Nazionale Tumori- IRCCS- Fondazione G. Pascale, Napoli, Italy
16 Hematology-Oncology and Stem Cell Transplantation Unit, Department of Onco-Hemotology and Innovative Diagnostics, Istituto Nazionale Tumori- IRCCS- Fondazione G. Pascale, Napoli, Italy
17 SCDU Ematologia, IRCSS AOU SS Antonio, Biagio e Cesare Arrigo, Alessandria, Italy
18 SOC Clinica Ematologica – Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
19 Division of Hematology, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
20 Hematology Unit, Department of Medicine University of Padova, Padova, Italy
21 Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy
22 Hematology Unit, Department of Medicine University of Padova, Padova, Italy
23 Division of Hematology, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
24 Department of Medical Sciences, Macedonian Academy of Sciences and Arts, Skopje, Macedonia
25 Hematology Division, Santa Chiara Hospital, Trento, Italy
26 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081, Aviano, Italy
27 Hematology Unit, Department of Medicine University of Padova, Padova, Italy
28 Hematology Unit, Department of Medicine University of Padova, Padova, Italy
29 Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy, Università Cattolica del Sacro Cuore, Rome, Italy

Background Accelerated chronic lymphocytic leukemia (aCLL) and Richter transformation (RT) are two distinct aggressive forms of CLL, which may occur in around 1% and in 2-10% of patients, respectively. The Ginè criteria define aCLL as CLL with expanded proliferation centers, a mitosis count exceeding 2.4 or Ki67 expression greater than 40% per proliferation center, but lacking the morphological features of Diffuse Large B-Cell Lymphoma (DLBCL). Accurate histopathological assessment is essential, as aCLL may respond to standard therapies for CLL, to which RT is refractory. In real-world practice, patients presenting with suspected CLL transformation often require immediate intervention, frequently leading to empirical therapy initiation before a centralized histopathological review can be completed.

Aims The aim of this study was to develop a multi-parameter score based on easily accessible histological, biological, laboratory and metabolic parameters, to facilitate the distinction between aCLL and RT in clinical practice.

Methods A total of 158 patients with transformed CLL, 72 with aCLL and 86 with DLBCL-RT, were enrolled, from 9 different Italian centers between 2000 and 2025. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. For each case of aCLL and for 31 of the 86 patients with RT, a histopathological re-evaluation was carried out according to the Ginè criteria by an experienced haematopathologist specializing in lymphoid neoplasms. We retrospectively collected clinical and laboratory data (stage, lymph node and/or extranodal involvement, B symptoms, LDH levels, cytogenetic aberrations, TP53 and NOTCH1 mutations, IGHV mutation status), immunohistochemical parameters (Ki-67, CD5, CD23, PD-1, EBER, p53, cyclin D1, LEF1) and PET/CT metabolic data (SUVmax). Variables showing a statistically significant difference were first included in a univariate logistic regression model, then in a multivariate model.

Results Median time from CLL to aCLL diagnosis was 42 months (IQR: 0.3–109 months) and for RT diagnosis 55 months (IQR: 17–116 months), with a median age at diagnosis of 70 years (IQR: 63–77 years) and 67 years (IQR: 63–73 years), respectively. In the univariate analysis, the following parameters were significant: Ki-67 > 60%, CD5 and CD23 (all p < 0.001), p53 (p = 0.035), LDH >2 times the upper limit of normal (ULN; p = 0.004), B symptoms (p < 0.001), extranodal involvement (p = 0.003), SUVmax > 9 (p < 0.001), and at least one previous line of therapy (p = 0.001). Based on the multivariate analysis, we developed a final score that included 3 covariates: Ki-67 (or SUVmax), CD23, and LDH. The model assigned 2 points for Ki-67 > 60% (or SUVmax > 9 if Ki-67 was not available), 1 point for LDH > 2 × upper limit of normal, and 1 point for CD23 negativity, with the sum of these points defining the final score. If the score is 0, 1, 2, 3, 4, RT probability is 9.8% (4/41), 30% (3/10), 72.2% (13/18), 94.1% (16/17), 100% (9/9), respectively; the probability of aCLL is the complement of the RT probability. Finally, univariate analysis highlighted further distinctive features: RT patients presented significantly higher rates of extranodal disease, systemic B symptoms, prior therapy exposure, and CD5 loss (24% in RT vs 0% in aCLL, p < 0.001). Although CD5 loss could not be included in the multivariate model due to complete statistical separation, it strongly points toward DLBCL-RT. The model is based on a final sample of 95 patients, 45 RT and 50 aCLL, with all data available and has an optimal AUC 0.91 (CI: 0.84-0.97).

Conclusions: Differentiating aCLL from RT is critical and requires expert histopathological evaluation. A multiparametric score could help in differentiating the two entities, complementing the metabolic parameters obtained from PET/CT and histopathological findings. As this tool is based on routine, easily accessible parameters, it could reduce interobserver variability among pathologists and provide valuable support for centers lacking specialized histopathology. In conclusion, while histopathological evaluation remains the gold standard, our score provides a rapid, objective surrogate to guide timely therapeutic decisions and avoid unnecessary chemo-immunotherapy in aCLL. Standardizing pathology reports and integrating clinical-laboratory parameters will be key. Prospective validation is warranted to confirm these preliminary findings.
Luca Laurenti Sr, MD: AbbVie - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony)